vida: extract claims from 2026-05-05-northwestern-agrp-neurons-semaglutide-starvation-mechanism

- Source: inbox/queue/2026-05-05-northwestern-agrp-neurons-semaglutide-starvation-mechanism.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -31,3 +31,10 @@ This review establishes that GLP-1 receptor agonists create opposing clinical ou
 **Source:** NBC News 2024-08-15
 
 Clinicians describe progression from beneficial appetite suppression to pathological restriction, with 'atypical anorexia nervosa' pattern emerging. Cynthia Landrau case shows restrictive eating pattern (consuming one-third recommended calories) developing after initial appetite suppression benefit.
+
+
+## Extending Evidence
+
+**Source:** Northwestern Medicine JCI 2025, Dr. Beutler
+
+Northwestern's AgRP neuron silencing mechanism provides the neurological explanation for subtype-specific risk. For restrictive eating disorders (anorexia nervosa, atypical anorexia), semaglutide removes the AgRP-mediated biological alarm that would normally trigger compensatory hunger during dangerous weight loss. For binge eating disorder, the same mechanism may be protective by reducing the hedonic drive to eat. The 'double whammy' of fullness signaling PLUS starvation-protection removal creates asymmetric risk profiles across ED subtypes.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -38,3 +38,10 @@ VigiBase analysis quantifies eating disorder signal magnitude at aROR 4.17-6.80
 **Source:** ANAD 2026 clinical guidance
 
 ANAD (the authoritative US professional society for eating disorders) formalizes the screening gap: they recommend tri-specialist evaluation (physician + therapist + dietitian all versed in both GLP-1s and eating disorders) before prescribing, but acknowledge this has zero regulatory force. The gap between recommended practice and actual practice (no screening required, telehealth prescribing without evaluation) is the operational measurement of the structural failure.
+
+
+## Extending Evidence
+
+**Source:** Northwestern Medicine JCI 2025
+
+The AgRP silencing mechanism strengthens the case for mandatory (not just recommended) pre-treatment screening. If semaglutide pharmacologically removes the biological safeguard against starvation, prescribing without ED screening is analogous to removing a safety system without checking if backup protections exist. The mechanism suggests screening should specifically assess for restrictive eating patterns, not just diagnosed eating disorders.

domains/health/semaglutide-silences-agrp-starvation-neurons-amplifying-behavioral-determinism.md

@@ -0,0 +1,23 @@
+---
+type: claim
+domain: health
+description: GLP-1 receptor agonists pharmacologically suppress the AgRP neuron activation that normally protects against starvation during weight loss, removing biological safeguards and making behavioral context more determinative of malnutrition risk
+confidence: experimental
+source: Northwestern Medicine/Feinberg School of Medicine, Journal of Clinical Investigation 2025
+created: 2026-05-05
+title: Semaglutide silences AgRP starvation-protection neurons, amplifying the relative importance of behavioral and social factors in determining eating disorder risk
+agent: vida
+sourced_from: health/2026-05-05-northwestern-agrp-neurons-semaglutide-starvation-mechanism.md
+scope: causal
+sourcer: Northwestern Medicine
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing"]
+related: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+---
+
+# Semaglutide silences AgRP starvation-protection neurons, amplifying the relative importance of behavioral and social factors in determining eating disorder risk
+
+Northwestern researchers identified a 'double whammy' mechanism for semaglutide's appetite suppression: it both signals fullness through standard GLP-1R agonism AND silences AgRP neurons that normally activate during negative energy balance to protect against starvation. Dr. Beutler describes AgRP neurons as the body's biological alarm system that 'protect the body from starvation' by triggering compensatory hunger when weight loss occurs. Semaglutide pharmacologically counteracts this protective response—even as the body loses weight and would normally activate AgRP neurons to prevent progression to malnutrition, the drug prevents this compensatory signal from occurring.
+
+This mechanism provides a neurological explanation for why behavioral, social, and environmental factors become MORE (not less) determinative of eating disorder risk in GLP-1 users. By removing the biological safeguard (the 10-20% clinical domain in the health outcomes framework), semaglutide increases the relative weight of the behavioral/social domain (the 80-90% non-clinical factors). The drug doesn't create eating disorders directly—it removes the biological brake that would otherwise limit progression to malnutrition, making pre-existing behavioral vulnerabilities, social pressures, and environmental cues the primary remaining protection.
+
+The study was conducted in mice, so human translation is plausible given well-characterized GLP-1 receptor distribution but not yet confirmed at the level of AgRP-specific silencing in humans. The researchers framed this entirely as a therapeutic mechanism without discussing eating disorder implications—the risk inference requires applying the mechanism to ED-vulnerable populations.

inbox/archive/health/2026-05-05-northwestern-agrp-neurons-semaglutide-starvation-mechanism.md

@@ -7,10 +7,13 @@ date: 2025-10-23
 domain: health
 secondary_domains: [ai-alignment]
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, semaglutide, agrp-neurons, mechanism, appetite, starvation, neurological, eating-disorders]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content